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A previous evaluation of the insulin-like activity of three 3-hydroxy-4-pyridinonato oxidovanadium(IV)
complexes raised questions about structure/activity relationships, namely the inﬂuence of the hydro-
philic/lipophilic balance of the complex and the capacity of the ligand to stabilize the +4 oxidation state
of vanadium ion, on achieving an positive effect. To address these questions, we synthesized six new oxi-
dovanadium(IV) complexes with variable hydrophilic/lipophilic balance, obtained by introducing differ-
ent substituents on the nitrogen atom, and used two 3-hydroxy-4-pyrones as starting reagents to provide
methyl and ethyl groups in the ortho position of the ring. For the new and previously reported complexes,
we studied the oxidation–reduction properties and insulin-like activity in terms of inhibitory effect on
Free fatty acid (FFA) release in isolated rat adipocytes. The results obtained show that only one of the
complexes, Bis(3-hydroxy-1(H)-2-methyl-4-pyridonato)oxidovanadium(IV), VO(mpp)2, exhibits a signiﬁ-
cantly greater capacity to inhibit FFA release than VOSO4 and consequently is worthy to be considered
for further studies. The establishment of structure activity relationships was not attainable but this study
brings new information about the inﬂuence of some properties of the compounds on the achievement of
an insulin-like effect. The results reveal that: (i) the oxidation–reduction cycles of the complexes are
identical; (ii) the presence of more lipophilic substituents on the nitrogen atom does not enhance insu-
lin-like properties; (iii) a high solubility in water proved to be not sufﬁcient for a positive activity in
inhibiting FFA release; (iv) a small molecular size may be an important property for reaching the right
targets.
 2009 Elsevier Inc. All rights reserved.1. Introduction
Diabetes Mellitus is a condition characterized by abnormal glu-
cose levels with a tendency to hyperglycaemia, due to a relative
or absolute deﬁciency of insulin. Unfortunately, many people still
die as a direct consequence of the disease or its associated pathol-
ogies. The incidence of the disease has increased along the years
and the number of patients is expected to be 300 million in 2025.
The ﬁrst report of the effectiveness of a vanadium compound in
improving the diabetic state of patients dates the year of 1899 [1],
a time in which vanadium was expected to cure all kinds of dis-
eases. However, only in the last quarter of the 20th century an ac-
tive search of a vanadium compound that could be administeredll rights reserved.
: +351 220402659.orally and produce insulin-like effects has been initiated. A large
number of studies regarding the synthesis of novel vanadium com-
plexes bearing different coordination spheres and its potential
insulin enhancing properties has now been reported and several
review papers collecting the overall information have been pub-
lished [2–8]. The oxidovanadium(IV) complex of ethylmaltol
(BEOV) has passed Phase I clinical trials in 2000 and recently Phase
II clinical trials [9].
Our group has long been interested in the chemistry of 3-hydro-
xy-4-pyrone and 3-hydroxy-4-pyridinones and their complexes, as
the ligands are synthetically versatile, have interesting structural
and solvation properties and in particular have a strong afﬁnity to-
wards M(III) and M(II) metal ions forming a large variety of com-
plexes [10]. Ligands and complexes ﬁnd applications in many
areas, namely the regulation of metal ions in the body and
development of new drugs. In order to provide a new family of
complexes with potential insulin enhancing properties we have
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3-hydroxy-4-pyridinones [11–17].
Some years ago we reported the ﬁrst in vitro evaluation of insu-
lin-like action of three oxidovanadium(IV) complexes derived from
3-hydroxy-4-pyridinones based on the inhibition of free fatty cid
(FFA) release in isolated rat adipocytes [14]. The results obtained
pointed out two complexes with a positive effect and raised some
questions in what concerns the possible establishment of struc-
ture/activity relationships namely the inﬂuence of hydrophilic/
lipophilic balance of the complex and the capacity of the ligand
to stabilize the +4 oxidation state of vanadium ion.
In order to address those questions we synthesized six new
complexes derived from ligands with the methyl and ethyl groups
in the ortho position and with variable hydrophilic/lipophilic bal-
ance, provided by different substituents on the nitrogen atom of
the heterocyclic ring. Here, we report the synthesis and character-Fig. 1. Formulae and abbreviation of the oxidovanadium(IV) comization of the novel complexes and the study of oxidation–reduc-
tion cycles and insulin-like activity, in terms of inhibitory effect
on free fatty acid release in isolated rat adipocytes, for the new
and the previously described complexes. The formulae and abbrevi-
ations of the complexes under study are depicted in Fig. 1.2. Experimental
2.1. Chemicals
The ligands were prepared according to established procedures
described for 3-hydroxy-4-pyridinones [10,18,19]. All other chem-
icals were from Aldrich (grade Puriss. P.A.). The solvents were dis-
tilled under argon and degassed prior to use in order to avoid
oxidation of the complexes.plexes with 3-hydroxy-4-pyridinones studied in this work.
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The [VIVOL2] complexes were prepared under anaerobic
conditions using an argon/vacuum line and Schlenk type glass-
ware. We prepared a solution of 20 mmol of VOSO4 dissolved in
the minimum amount of water required to complete dissolution
and a solution of 20 mmol of the ligand dissolved in the minimum
amount of water or an ethanol/water mixture (40:60), in the case
of more lipophilic compounds. The two solutions were added
slowly and the pH adjusted to 9 with a solution of NaOH. The
reaction media was reﬂuxed, under argon, for about 1 h. The
blue/greyish powders that precipitate were ﬁltered while the
solution was still warm and dried in vacuum over P2O5. The yield
is typically ca 70% and the compounds were characterized by
elemental analysis, fast atom bombardment mass spectrometry
(FAB), FTIR spectroscopy, UV/visible spectroscopy and EPR
spectroscopy.
2.2.1. Bis (3-hydroxy-1(H)-2-ethyl-4-pyridonato)oxidovanadium(IV),
VO(etpp)2
Anal. Calcd (Found): C14H16N2O5V: %C 48.99 (49.15); %H 4.70
(4.64); %N 8.16 (8.04) FTIR (KBr) m (cm1): 3038 (mOH); 1607
(mC@O); 1555–1499; (mC@C); 1257, 1066 (mC–O); 708, 651 (mV–O);
980 (mV@O); UV/visible (DMSO) (kmáx (nm) (e M1 cm1)): 672
(149), 621 (65), 543 (80), 426 (150); mass spec. m/z (FAB): 344
(ML2H+).
2.2.2. Bis (3-hydroxy-1-(ethyl)-2-methyl-4-pyridonato)-
oxidovanadium(IV), VO(mepp)2
Anal. Calcd (Found): C16H20N2O5V: %C 51.75 (51.70); %H 5.44
(5.37); %N 7.55 (7.53) FTIR (KBr) m (cm1): 3038 (mOH); 1607
(mC@O); 1555–1499; (mC@C); 1257, 1066 (mC–O); 708, 651 (mV–O);
967 (mV@O); UV/visible (DMSO) (kmáx (nm) (e M1 cm1)) 672
(149), 621 (65), 543 (80), 426 (150); mass spec. m/z (FAB): 372
(ML2H+).
2.2.3. Bis (3-hydroxy-1-(2-hydroxyethyl)-2-methyl-4-pyridonato)-
oxidovanadium(IV), VO(hempp)2
Anal. Calcd (Found): C16H20N2O7V: %C 47.82 (47.65); %H 5.00
(5.00); %N 6.91 (6.95) FTIR (KBr) m (cm1): 3038 (mOH); 1607 (mC@O);
1555–1499; (mC@C); 1257, 1066 (mC–O); 708, 651 (mV–O); 970
(mV@O); UV/visible (DMSO) (kmáx (nm) (e M1 cm1)) 672 (149),
621 (65), 543 (80), 426 (150); mass spec.m/z (FAB): 444.1 (ML2H+).
2.2.4. Bis (3-hydroxy-1-(2-hydroxyethyl)-2-ethyl-4-pyridonato)-
oxidovanadium(IV), VO(heepp)2
Anal. Calcd (Found): C18H24N2O7V: %C 50.05 (50.12); %H 5.62
(5.61); %N 6.43 (6.49) FTIR (KBr) m (cm1): 2970 (mOH); 1603
(mC@O); 1550–1488; (mC@C); 1227, 1087 (mC–O); 702, 625 (mM–O);
961 (mV@O); UV/visible (DMSO) (kmáx (nm) (e M1 cm1)) 700
(127), 608 (86), 536 (54), 434 (170); mass spec. m/z (FAB):
431.33 (ML2H+).
2.2.5. Bis (3-hydroxy-2-methyl-1-propil-4-pyridonato)-
oxidovanadium(IV), VO(pmpp)2
Anal. Calcd (Found): C18H24N2O5V: %C 54.43 (54.24); %H 5.78
(6.06); %N 6.92 (7.02) FTIR (KBr) m (cm1): 1602 (mC@O); 1344;
(mC@C); 1276, 978 (mC–O); 718, 576 (mM–O); 978 (mV@O); UV/visible
(DMSO) (kmáx (nm) (e M1 cm1)) 711 (17), 617 (57), 550 (55),
405 (137); mass spec. m/z (FAB): 399.3 (ML2H+).
2.2.6. Bis (1-hexyl-3-hydroxy-2-methyl-4-pyridonato)-
oxidovanadium(IV), VO(hmpp)2 H2O
Anal. Calcd (Found) for: C24H36N2O5VH2O: %C 57.89 (57.48); %H
7.55 (7.64); %N 5.54 (5.59) FTIR (KBr) m (cm1): 1604 (mC@O); 1340;
(mC@C); 1276, 978 (mC–O); 718, 574 (mV–O); 978 (mV@O); UV/visible(DMSO) (kmáx (nm) (e M1 cm1)) 712 (19), 616 (63), 550 (61),
402 (147); mass spec. m/z (FAB): 483.2 (ML2H+).
The synthesis of complexes, VO(mpp)2, VO(dmpp)2 and
VO(empp)2, which are also used in the present work, has already
been described and the structure of these compounds was
analyzed by extended X-ray absorption ﬁne structure (EXAFS)
[17].
2.3. Spectroscopic and analytical measurements
Solutions of the complexes under study were prepared in DMF
and DMSO under anaerobic conditions. EPR spectra were recorded
in frozen solution at 100 K using an X-band (9.15 GHz) Bruker EMX
spectrometer. The spectra were simulated with the computer suite
program Bruker WinEPR/SimFonia. UV/visible spectra were ob-
tained with a Unicam-UV 300 spectrometer and deconvoluted with
Origin. Elemental analysis (C, H, N) were performed at the Micro-
analytical Laboratory of the University of Manchester, UK. Fast
atom bombardment (+FAB) mass spectra were obtained using a
Kratos concept double focusing mass spectrometer at the Univer-
sity of Santiago.
2.4. Cyclic voltammetry (CV)
Cyclic voltammetry of the VO(IV) complexes (0.5–1.0 mM) was
performed in DMF, at room temperature using an Autolab
PGSTAT20 potentiostat/galvanostat. We used a three-electrode cell
composed by a Pt disk electrode with an area of 0.0314 cm2 as the
working electrode, a Pt gauze electrode as the counter electrode
and a Ag/AgCl (1 M NaCl Metrohm, Ref. 6.0724.140) as the refer-
ence electrode. Tetrabutylammonium perchlorate (TBAP) was used
as the supporting electrolyte. The ferrocene/ferrocenium redox
couple was used as internal standard and under the experimental
conditions used in the present work, E1/2 for Fc/Fc+ couple was
0.46 V in DMF. Prior to use, the Pt working electrode was polished
with an aqueous suspension of 0.05 lm alumina (Beuhler) on a
Master-Tex (Beuhler) polishing pad, then rinsed with water and
acetone and dried. All solutions were de-aerated in the cell by a
stream of argon. In all experiments we have used the following
parameters: scan rates in the interval 0.05–0.5 V s1 and the po-
tential limits were 1.0 and 0.1 V.
2.5. Animal studies
Male Wistar rats were sacriﬁced under anesthesia with ether.
The adipose tissues were removed, chopped with scissors and di-
gested with collagenase for 60 min at 37 C in Krebs Ringer bicar-
bonate buffer (120 mM NaCl, 1.27 mM CaCl2, 1.2 mM MgSO4,
4.75 mM KCl, 1.2 mM KH2PO4, 24 mM NaHCO3: pH 7.4), containing
2% BSA (bovine serum albumin). The obtained adipocytes were
then separated from undigested tissues by ﬁltration through nylon
mesh and washed three times. The metal complexes were dis-
solved in saline or DMSO at various concentrations (ﬁnal conc.;
0.1, 0.25, 0.5, and 1 mM) by ultrasonic disintegrating and glucose
(ﬁnal conc.; 5 mM) were added to the isolated rat adipocytes.
The resulting suspensions were incubated at 37 C for 30 min. Fi-
nally, epinephrine solution (ﬁnal conc.; 10 lM) was added to the
reaction mixtures, and the resulting solutions were incubated at
37 C for 180 min. The reactions were stopped by soaking in ice
water, and the mixtures were centrifuged at 3000 rpm for
10 min. FFA (free fatty acids) levels in the outer solution of the cells
were determined using an FFA kit (NEFA C-test WAKO, Wako Pure
Chemicals). The in vitro insulin-mimetic activity of the complexes
was evaluated by the IC50 value, which deﬁnes the concentration
of the complex required for 50% inhibition of FFA release from
the isolated rat adipocytes treated with epinephrine.
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Fig. 2. Electronic absorption spectrum of VO(mpp)2 in a DMF solution recorded in
the following conditions: (a) anaerobic conditions; (b) exposed to air for 24 h, (c)
exposed to air for 48 h.
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Fig. 3. Electronic absorption spectrum of VO(mpp)2 in a DMF solution and its
deconvolution into four components. The solid line is the experimental spectrum
and the dashed, dot-dashed and dot-dot-dashed lines are deconvoluted spectra.3. Results and discussion
3.1. Chemistry
Ligands of the 3-hydroxy-4-pyridinone type are generally pre-
pared by reaction of 3-hydroxy-4-pyrones and primary amines
using either a direct method or a synthetic route in which the hy-
droxyl group is protected according to the nature of the amine
[10,18,19]. In order to provide a set of ligands that could be used
to investigate the inﬂuence of hydrophilic/lipophilic balance and
the effect of electron donation in position 2 of the heterocyclic ring
our approach was to use two different pyrones, 3-hydroxy-2-
methyl-4-pyrone and 3-hydroxy-2-ethyl-4-pyrone and make them
react with a set of primary amines of variable lipophilicity. In this
way, we produced a set of ligands with variable hydrophilic/lipo-
philic balance, which have different solubility in water, different
molecular size and different ability to stabilize the +4 oxidation
state. The corresponding oxidovanadium(IV) complexes also exhi-
bit variable properties as can be inferred from their formulae
(Fig. 1).
The oxidovanadium(IV) complexes were synthesized using the
experimental procedure previously described by us [11,17]. The
complexes are isolated as blue/greyish powders and the Elemental
Analysis results are consistent with VOL2 or VOL2H2O stoichiome-
tries. In the solid state the compounds are stable under aerobic
conditions. If the compounds are ﬁltered while the solution is still
hot it is not obligatory to perform the synthesis under an argon
atmosphere although we usually do it in order to prevent
oxidation.
As had already been observed for the complexes synthesized
previously, VO(mpp)2, VO(dmpp)2 and VO(empp)2, no crystals
suitable for X-ray Diffraction analysis have been isolated, a difﬁ-
culty which is attributed to the fact that in some solvents the com-
plexes undergo rapid oxidation and two isomeric forms are present
[11].
The structure of compounds VO(mpp)2, VO(dmpp)2 and
VO(empp)2 was analyzed by us using EXAFS spectroscopy [17].
The results obtained indicate that the non-hydrated compounds,
VO(dmpp)2 and VO(empp)2, are ﬁve-coordinate, showing one oxy-
gen atom at 1.60 Å and four oxygen atoms at 1.95 Å. The com-
pound VO(mpp)2 was isolated with a bound water molecule
detected at 2.3 Å and occupying the sixth coordination position.
The vanadium–oxygen bond lengths do not vary signiﬁcantly be-
tween the various pyridinone complexes, thus showing that the lo-
cal structure around the metal centre is not appreciably modiﬁed
by changing the substituents on the ring nitrogen atom. An identi-
cal conclusion was obtained from an EXAFS study of a group of ir-
on(III) complexes of similar 3-hydroxy-4-pyridinones [20] and
both analyses corroborate the fact that the hidrophilic/lipophilic
balance of the 3-hydroxy-4-pyridinone complexes can be tuned
without signiﬁcantly altering the local structure around the metal
centre.
At room temperature the compounds are soluble in water or
water/alcohol mixtures, alcohols, N,N-dimethylformamide (DMF)
and DMSO. Under anaerobic conditions the complexes remain in
the +4 oxidation state but undergo oxidation in the presence of
air. In order to illustrate this fact the UV/visible spectra of a DMF
solution of the compound VO(mpp)2 are shown, in Fig. 2 under
anaerobic conditions and in the presence of air after 24 and 48 h
exposure. The spectrum obtained after 48 h, exhibiting an intensecharge transfer band at 512 nm, is identical to the one obtained by
chemical oxidation of the vanadium(IV) complex with potassium
peroxodisulfate and is assigned to the species [VO2(mpp)2]+. More-
over, the rate of the oxidation process is solvent-dependant, being
instantaneous in water and alcohols and slower in DMF and DMSO
as can be gathered by the changes observed in the UV/visible and
EPR spectra which loose intensity and become silent after a few
days.
The characterization of the electronic structure of the com-
plexes in solution has been achieved by a combined study of UV/
Visible spectroscopy and EPR in frozen solution. Electronic spectra
are characterized by four absorption bands in the visible region,
three of which are clearly distinguished and a fourth one which
is noticeable as a shoulder and that can be resolved by spectra
deconvolution as shown in Fig. 3. For a square-pyramidal geometry
of C4v symmetry, with the z-axis taken as the vanadium–oxygen
double bond and the x- and y-axes along the equatorial bonds,
three transitions are expected 2B2ðdxyÞ ! 2Eðdxz;dyzÞ; 2B2ðdxyÞ !
2B1ðdx2z2 Þ and 2B2ðdxyÞ ! 2A1ðdz2 Þ. The presence of a fourth transi-
tion is due to the splitting of the 2E(dxz, dyz) state in lower
symmetry.
The EPR spectra obtained in frozen solution are typical of VOL2
complexes and are characteristic of the interaction of one unpaired
Table 2
Voltammetric data for the compound VO(heepp)2 (DMF, 0.1 M TBAP). Scan rates 500,
200, 100, 50 mV s1.
t/mV s1 Epa/V Epc/V DE/V E1/2/V ipa/ipc
500 0.57 ± 0.06 0.27 ± 0.04 0.30 ± 0.11 0.42 ± 0.02 0.92 ± 0.13
200 0.54 ± 0.06 0.29 ± 0.04 0.25 ± 0.11 0.42 ± 0.02 0.98 ± 0.12
100 0.53 ± 0.08 0.29 ± 0.04 0.23 ± 0.14 0.41 ± 0.02 1.00 ± 0.12
50 0.50 ± 0.08 0.31 ± 0.03 0.20 ± 0.10 0.41 ± 0.02 1.08 ± 0.12
0.0 0.2 0.4 0.6 0.8 1.0
-5.0x10-6
0.0
5.0x10-6
i/A
Potential/V
Fig. 5. Cyclic voltammogram of VO(heepp)2 (DMF, 0.1 M TBAP). Scan rates 500, 200,
100, 50 mV s1.
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Magnetic Field (Gauss)
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Fig. 4. Frozen solution (100 K) EPR spectrum of VO(mepp)2 in a DMF solution.
Experimental spectrum (top, solid line), simulated spectrum (bottom, dotted line).
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spectra obtained for all the compounds studied are almost identi-
cal. The experimental spectra have been simulated assuming three
different g values and matching of experimental and simulated
spectra has been obtained for a set of values shown in Table 1
for the compound VO(mepp)2.
The observation of a four band pattern in the UV/visible spectra
together with EPR spectra characterized by three different g values
is a criterion to reveal the existence of a distortion of the VIVO com-
plexes from a square-pyramidal towards a trigonal-bipyramidal
geometry [11]. According to the parameters obtained for the elec-
tronic and EPR spectra, we conclude that the new oxidovanadi-
um(IV) complexes described in this work exhibit a square planar
geometry with a moderate distortion towards a trigonal-bipyrami-
dal geometry as has been observed for the other oxidovanadi-
um(IV) complexes with 3-hydroxy-4-pyridinones.
The UV/visible spectroscopy and the EPR results obtained con-
ﬁrm that for the complexes studied in this work the properties of
the metal centre are not signiﬁcantly changed as the hydrophilic/
lipophilic balance of the ligand is modiﬁed by introducing different
substituents on the heterocyclic nitrogen atom and we consider
that the new complexes exhibits structures identical to those pre-
viously studied by EXAFS [17].
In order to get insight on the oxidation–reduction cycles of the
complexes and to understand if this behavior is inﬂuenced by the
changes in the substituents of the ligands we studied the redox
properties of the complexes, that were enough soluble within the
experimental conditions, by cyclic voltammetry in DMF. The re-
sults obtained are very similar for all the complexes and are shown
in Table 2 for the complex VO(mepp)2. As an example the voltam-
mogram of the complex VO(mepp)2 is shown in Fig. 5.
All the studied complexes exhibit one anodic wave and the cor-
responding cathodic wave. For the majority of the complexes an-
other ill deﬁned and low intensity pre-anodic wave is observed.
Analysis of the CV data in the redox process observed for all the
VO complexes reveals: (a) a linear dependence of ip with t1/2; (b)
anodic–cathodic peak potential separation (DE) that is higher than
that of the Fc+/Fc couple; (c) variation of the scan rate between 50
and 500 mV s1 showed a decrease in DE values; (d) ipc/ipa ratios
are close to 1, but show a slight increase with the scan rate.Table 1
Spin Hamiltonian parameters for the compound VO(mepp)2.
gx 1.985 ± 0.002 Ax 46 ± 1  104 cm1
gy 1.978 ± 0.003 Ay 53 ± 1  104 cm1
gz 1.952 ± 0.004 Az 158 ± 1  104 cm1These results suggest that the process is diffusion-controlled,
but with a certain degree of irreversibility [21]. That is in agree-
ment with a quasi-reversible V(IV)? V(V) oxidation process which
is expected, since it can be foreseen that changes in the coordina-
tion sphere of the complex may occur in the oxidation–reduction
process, namely the exchange of solvent molecules. In a previous
study such changes have been observed in the EPR spectra of
DMSO solutions [11].
The similarity of the CV results observed for all the compounds
signiﬁes that the redox properties of the oxovanadium(IV) com-
plexes are not signiﬁcantly modiﬁed by varying the lipophilicity
of ligand and that the redox process may be essentially assigned
to the metal centre.
3.2. Insulin-mimetic properties
It is known from in vivo studies that the serum level of FFA is a
good index to know the degree of diabetes mellitus and also that
both serum glucose and FFA levels in streptozotocin-induced dia-
betic rats (STZ-rats) are normalized by vanadyl treatment. Vanadyl
ion enhances glucose uptake in peripheral adipocytes, therefore,
the use of adipocytes gives valuable information on the mechanism
of vanadium-dependent normalization of both serum glucose and
FFA levels in STZ-rats [22–25].
The insulin enhancing potential of the vanadium complexes
with 3-hydroxy-4-pyridinones prepared in this work was tested
performing in vitro experiments in which the inhibition of FFA re-
lease in rat adipocytes was measured in the presence of the
complexes.
The results obtained for the complexes which were enough
soluble together with those obtained for a blank and for vanadyl
sulfate are shown in Fig. 6. In order to evaluate the dependence
of the inhibitory effect on concentration, solutions of three
1. blank, 2. control, 3. VS 0.1 mM, 4. VS 0.5 mM, 5. VS 1 mM, 
6. VM 0.1 mM, 7. VM 0.5 mM, 8. VM 1 mM, 9. VEt 0.1 mM, 10. VEt 0.5 mM, 
11. VEt 1 mM, 12. VDm 0.1 mM, 13. VDm 0.5 mM, 14. VDm 1 mM, 15. VMe 0.1 mM, 
16. VMe 0.5 mM, 17. VMe 1 mM, 18. VEm 0.1 mM, 19. VEm 0.5 mM, 20. VEm 1 mM, 
21. VDe 0.1 mM, 22.VDe 0.5 mM, 23. VDe 1 mM, 24. VHem 0.1 mM, 25. VHem 0.5 mM, 
26. VHem 1 mM, 27. VHee 0.1 mM, 28. VHee 0.5 mM, 29. VHee 1 mM  
VOSO4: VS, VO(mpp)2: VM, VO(etpp)2: VEt, VO(dmpp)2: VDm, VO(mepp)2: VMe, VO(empp)2: VEm, 
VO(depp)2: VDe, VO(hempp)2: VHem, VO(heepp)2: VHee. 
0
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Fig. 6. Inhibitory effects of VOSO4 and oxidovanadium(IV) complexes with 3-hydroxy-4-pyridinone derivatives on FFA release from rat adipocytes treated with epinephrine.
Data are expressed as the means ± SDs for three experiments.
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values of IC50, 50% inhibition concentration, are summarized in
Table 3.
It is noticeable from Fig. 6 that the complexes VO(mpp)2 (bars 6,
7, 8) and VO(etpp)2 (bars 9, 10, 11) have a considerable dose
dependant response comparable with VOSO4 (bars 3, 4, 5) and that
the complex VO(mpp)2 shows a better performance than the inor-
ganic salt. All the other complexes have a very poor effect when
compared to that observed for VOSO4. Surprisingly, the values ob-
tained for the complexes VO(dmpp)2 and VO(empp)2 are different
from the previously obtained in an independent study [14] and in
particular we could not ﬁnd a response for the latter complex
although several attempts have been tried.
Solubility in water by itself does not seem to be the only prop-
erty required for positive activity as the compounds VO(hempp)2
and VO(heepp)2 are at least as soluble VO(mpp)2 and VO(etpp)2.
Also, the different behavior in what concerns inhibition of FFA re-
lease cannot be accounted for by considering a different behavior/Table 3
Values of IC50 (mM) for inhibition of FFA in rat adipocytes.
Compound IC50 (mM) this work IC50 (mM) Ref. [14]
VOSO4 0.74 ± 0.04 3.20
VO(mpp)2 0.53 ± 0.04* 0.56
VO(etpp)2 0.75 ± 0.06 Not tested
VO(empp)2 None 0.56
VO(mepp)2 2.98 ± 0.6 Not tested
VO(dmpp)2 12.5 ± 5.5 1.36
VO(depp)2 None Not tested
VO(hempp)2 8.26 ± 3.3 Not tested
VO(heepp)2 None Not tested
* p < 0.05 vs. VOSO4.speciation in aqueous solution, as it is well known that the stability
constants of complexes formed by the same metal ion with 3-hy-
droxy-4-pyridinones of variable hydrophilic/lipophilic balance
are not signiﬁcantly modiﬁed.
Regarding the establishment of structure/activity relationships,
unfortunately we could not get insight in this subject from the
present results, although we perceive that a high solubility in
water and a small molecular size seem to be important properties
for achieving a positive effect. In what concerns oxidation–reduc-
tion properties we found that the redox cycles of the complexes
are not signiﬁcantly changed by the presence of more electron
donating groups in the ligand as can be gathered from results of
parent complexes derived from the pyrones with methyl and ethyl
groups in the ortho position.
As a ﬁnal conclusion we think that the most important result is
the fact that the present results do conﬁrm that the complex
VO(mpp)2 shows a signiﬁcantly better effect than the inorganic salt
and is worthy to be considered for animal studies.
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